AKARI THERAPEUTICS, PLC

(AKTX)
  Report
Delayed Nasdaq  -  03:59 2022-08-09 pm EDT
1.550 USD   +8.39%
08/05European ADRs Move Lower in Friday Trading
MT
08/04European ADRs Move Higher in Thursday Trading
MT
08/01AKARI THERAPEUTICS : Narrows Pipeline Focus - Form 6-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/03/2022 08/04/2022 08/05/2022 08/08/2022 08/09/2022 Date
1.26(c) 1.41(c) 1.4301(c) 1.43(c) 1.55 Last
193 049 167 117 124 299 167 752 118 450 Volume
-3.08% +11.90% +1.43% -0.01% +8.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022
Net income 2022
Net Debt 2022
P/E ratio 2022
Yield 2022
Sales 2023 - - -
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -143x
Yield 2023 -
Capitalization 84,9 M 84,9 M -
EV / Sales 2022
Capi. / Sales 2023 -
Nbr of Employees 9
Free-Float 64,2%
More Financials
Company
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5. Its lead product candidate, Nomacopan, is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b-9... 
More about the company
All news about AKARI THERAPEUTICS, PLC
08/05European ADRs Move Lower in Friday Trading
MT
08/04European ADRs Move Higher in Thursday Trading
MT
08/01AKARI THERAPEUTICS : Narrows Pipeline Focus - Form 6-K
PU
08/01Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs
CI
08/01ADRs End Lower, Akari Therapeutics and Alibaba Trade Actively
DJ
08/01Akari Therapeutics to Focus on Two Pipeline Programs
MT
08/01European ADRs Move Higher in Monday Trading
MT
08/01Akari Therapeutics Narrows Pipeline Focus
AQ
07/29AKARI THERAPEUTICS : Press release dated July 28, 2022 - Form 6-K
PU
07/28Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Inves..
AQ
07/28Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Inves..
CI
07/27European ADRs Move Higher in Wednesday Trading
MT
07/26European ADRs Move Lower in Tuesday Trading
MT
07/25European ADRs Move Higher in Monday Trading
MT
07/20AKARI THERAPEUTICS : Condensed Consolidated Financial Statements - Form 6-K
PU
More news
News in other languages on AKARI THERAPEUTICS, PLC
08/05Les ADR européens sont en baisse vendredi
08/04Les ADR européens sont en hausse jeudi
08/01Akari Therapeutics, plc annonce qu'elle donne la priorité à deux programmes en cours de..
08/01Akari Therapeutics va se concentrer sur deux programmes en cours de développement
08/01Les ADR européens progressent lundi
More news
Chart AKARI THERAPEUTICS, PLC
Duration : Period :
Akari Therapeutics, Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKARI THERAPEUTICS, PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
EPS Revisions
Managers and Directors
Rachelle Jacques President, Chief Executive Officer & Director
Torsten Hombeck Chief Financial & Accounting Officer
Raymond Prudo-Chlebosz Executive Chairman
Miles Nunn Chief Scientific Officer
Wynne Weston-Davies Medical Director
Sector and Competitors
1st jan.Capi. (M$)
AKARI THERAPEUTICS, PLC-4.67%85
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%75 386
REGENERON PHARMACEUTICALS, INC.-2.84%67 420
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.64%40 375